An in silico rational computer-aided designed of Antimicrobial Peptide-mimetic Psoriasin (S100A7) and Koebnerisin (S100A15) high binding free energy pharmacophoric hyper-scaffolds as a novel synthetic pharmaco-ligand with potential inhibitory activities for the Suppression of the Extracellular Matrix Production and Proliferation of Human Fibroblasts.

Keloids result from aberrations in the normal wound healing cascade and can lead to pruritus, contractures and pain. The underlying mechanisms of excessive scarring are not yet understood, and most therapeutic strategies remain unsatisfactory. Psoriasin (S100A7) and koebnerisin (S100A15) are released by keratinocytes during physiological wound healing. Psoriasin (S100A7) and koebnerisin (S100A15) are released by keratinocytes during physiological wound healing. S100 production is markedly decreased in keloid scar tissue. The disturbed epidermal S100 expression might contribute to keloid formation; thus, it has been previously studied their effect on dermal fibroblasts and extracellular matrix (ECM) production. Here, in Biogenea Pharmaceuticals Ltd we discovered for the first time the GENEA-AntiPsorerisin-10715. An in silico rational computer-aided designed of Antimicrobial Peptides Psoriasin (S100A7) and Koebnerisin (S100A15) mimetic pharmacophore for the Suppression of the Extracellular Matrix Production and Proliferation of Human Fibroblasts by Predicting interacting residues using long-distance information and novel decoding in hidden Markov models.